Latest Cynosure Inc (CYNO) Headlines
Mindray Medical International Slips to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 1:50PM CDT
Mindray has seen a negative trend in earnings estimate revisions in the past 7 days.
Varian Medical Systems Hit 52-Week High - Analyst Blog
Souvik Guha - Zacks Investment Research - Tue Mar 11, 12:38PM CDT
Shares of VAR started escalating following its announcement of several events supporting the increased adoption of the company's technology and the exhibition of a comprehensive line of products in the pipeline.
AngioDynamics Gets 3rd FDA Approval for BioFlo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 4:30PM CDT
The commercial launch of the catheter, which is expected in the fourth quarter of fiscal year 2014, is likely to boost ANGO's 15% share in the $100 million chronic dialysis catheter market.
Synergetics (SURG) in Focus: Stock Tumbles 11.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:59AM CDT
Synergetics' shares fell by over 11% on the day. This continues the recent downtrend for SURG, as the stock is down nearly 6% since Feb 13.
Shares of CYNO Up 28.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 06, 5:04PM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on November 7th, 2013 at $23.71. In approximately 4 months, Cynosure has returned 28.66% as of today's recent price of $30.50.
Thoratec Warns About HeartMate Controller - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:00PM CST
Investors reacted negatively to the news, resulting in a 2.7% fall in THOR shares to $36.22 after the market closed yesterday
Mindray Tops on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 2:23PM CST
International revenues grew 23.8% to $208.0 million while revenues from China grew at a slower pace of 8.3% to $160.4 million
HeartWare Sees Narrower Loss but Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:55AM CST
For full year 2013, HeartWare's loss was also narrower at $52.0 million or $3.24 per share compared with $86.6 million or $6.07 per share in 2012.
Teleflex Beats on Q4 Earnings, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 12:50PM CST
Following the favorable earnings announcement, shares of Teleflex rose 0.8% till the last closing date.
Cynosure Has Returned 30.8% Since SmarTrend Recommendation (CYNO)
Comtex SmarTrend(R) - Thu Feb 27, 11:07AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on November 7th, 2013 at $23.71. In approximately 4 months, Cynosure has returned 30.82% as of today's recent price of $31.01.
Fresenius Medical Care Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 9:20AM CST
For full-year 2013, FMS reported a 6.5% fall in net earnings to $1.1 billion and a 6% drop in net earnings per share to $1.83.
North America Weight Loss/Obesity Management Market - Forecasts to 2017: Featuring Players such as Atkins Nutritionals, Inc and Johnson & Johnson
M2 - Wed Feb 26, 9:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wj24jb/north_america) has announced the addition of the "North America Weight Loss/Obesity Management Market - Forecasts to 2017" report to their offering. Obesity and weight gain have always been major concerns in the health and fitness of individuals; today, it has reached the level of an epidemic. Increasing obesity rates and growing levels of awareness among calorie-conscious consumers in North America have opened up new avenues for the weight management industry. The North American weight loss/obesity management market was estimated to be worth $104 billion in 2012. The quick results of weight loss surgeries and insurance coverage have made bariatric surgeries popular among clinically obese people. However, the considerable side-effects of these weight loss surgeries have made people opt for non-invasive and non-medical methods of weight loss. As per the American Society for Metabolic & Bariatric Surgery, the total number of weight loss surgeries performed in the U.S. was 220,000 in 2012, likely to increase in the coming years due to the rising obesity rate. In Canadian hospitals, a total of 2,385 bariatric procedures were carried out in 2008-2009; a 92% increase from 2004-2005. This research report categorizes the North America weight loss/obesity management market into weight loss diets, fitness and surgical equipment, and services. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the market is comprehensively analyzed at a granular level by geography (U.S. and Canada) to provide in-depth information on the North American scenario. Companies Mentioned: - Ajinomoto Co, Inc - Allergan, Inc - Amer Sports Corporation - Brunswick Corporation - Cynosure, Inc - EdietsCom - Equinox - Fitness First Group, Ltd - Gold's Gym International, Inc - Herbalife, Ltd - Icon Health & Fitness, Inc - Johnson Health Tech Co, Ltd - Life Time Fitness, Inc - Lifecore Fitness - Nestle Sa - Nutrisystem, Inc - Olympus Corporation - Pepsico, Inc - The Coca-Cola Co - Weight Watchers International, Inc For more information visit http://www.researchandmarkets.com/research/wj...th_america About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
DexCom Beats, Sees Narrower Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:40AM CST
Owing to narrower reported loss or adjusted earnings in the 2013-fourth quarter, shares of Dexcom rose 3.5% since the announcement of earnings results
Why Cynosure (CYNO) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:54AM CST
Cynosure has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy
25.8% Return Seen to Date on SmarTrend Cynosure Call (CYNO)
Comtex SmarTrend(R) - Thu Feb 20, 9:43AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on November 7th, 2013 at $23.71. In approximately 4 months, Cynosure has returned 25.80% as of today's recent price of $29.82.
Why Cynosure (CYNO) Could Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 7:57AM CST
Cynosure, a medical instruments manufacturer, could be a great candidate for another earnings beat
Masimo Q4 Earnings Meet Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 2:43PM CST
For full year 2013, adjusted earnings per share rose 11.5% to $1.16, in line with the Zacks Consensus Estimate.
Cynosure, Inc. (CYNO) Looks Good: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 7:44AM CST
Cynosure, Inc. was a big mover last session, as the company saw its shares rise nearly 6% on the day.
17.6% Return Seen to Date on SmarTrend Cynosure Call (CYNO)
Comtex SmarTrend(R) - Thu Feb 13, 9:26AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on November 7th, 2013 at $23.71. In approximately 3 months, Cynosure has returned 17.61% as of today's recent price of $27.88.
Cynosure Reports Record Fourth Quarter Revenue of $74.5 million, up 75% Year-over-Year
PR Newswire - Wed Feb 12, 7:00AM CST
Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced financial results for the three and 12 months ended December 31, 2013. Revenues for the fourth quarter increased 75% to $74.5 million from $42.7 million for the same period of 2012, while revenues for the full year of 2013 were up 47% to $226.0 million from $153.5 million for 2012. The increase partly reflects the acquisition of Palomar Medical Technologies in June 2013.
Mindray Medical International Slips to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 1:50PM CDT
Mindray has seen a negative trend in earnings estimate revisions in the past 7 days.
Varian Medical Systems Hit 52-Week High - Analyst Blog
Souvik Guha - Zacks Investment Research - Tue Mar 11, 12:38PM CDT
Shares of VAR started escalating following its announcement of several events supporting the increased adoption of the company's technology and the exhibition of a comprehensive line of products in the pipeline.
AngioDynamics Gets 3rd FDA Approval for BioFlo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 4:30PM CDT
The commercial launch of the catheter, which is expected in the fourth quarter of fiscal year 2014, is likely to boost ANGO's 15% share in the $100 million chronic dialysis catheter market.
Synergetics (SURG) in Focus: Stock Tumbles 11.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:59AM CDT
Synergetics' shares fell by over 11% on the day. This continues the recent downtrend for SURG, as the stock is down nearly 6% since Feb 13.
Shares of CYNO Up 28.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 06, 5:04PM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on November 7th, 2013 at $23.71. In approximately 4 months, Cynosure has returned 28.66% as of today's recent price of $30.50.
Thoratec Warns About HeartMate Controller - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:00PM CST
Investors reacted negatively to the news, resulting in a 2.7% fall in THOR shares to $36.22 after the market closed yesterday
Mindray Tops on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 2:23PM CST
International revenues grew 23.8% to $208.0 million while revenues from China grew at a slower pace of 8.3% to $160.4 million
HeartWare Sees Narrower Loss but Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:55AM CST
For full year 2013, HeartWare's loss was also narrower at $52.0 million or $3.24 per share compared with $86.6 million or $6.07 per share in 2012.
Teleflex Beats on Q4 Earnings, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 12:50PM CST
Following the favorable earnings announcement, shares of Teleflex rose 0.8% till the last closing date.
Cynosure Has Returned 30.8% Since SmarTrend Recommendation (CYNO)
Comtex SmarTrend(R) - Thu Feb 27, 11:07AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on November 7th, 2013 at $23.71. In approximately 4 months, Cynosure has returned 30.82% as of today's recent price of $31.01.
Fresenius Medical Care Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 9:20AM CST
For full-year 2013, FMS reported a 6.5% fall in net earnings to $1.1 billion and a 6% drop in net earnings per share to $1.83.
North America Weight Loss/Obesity Management Market - Forecasts to 2017: Featuring Players such as Atkins Nutritionals, Inc and Johnson & Johnson
M2 - Wed Feb 26, 9:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wj24jb/north_america) has announced the addition of the "North America Weight Loss/Obesity Management Market - Forecasts to 2017" report to their offering. Obesity and weight gain have always been major concerns in the health and fitness of individuals; today, it has reached the level of an epidemic. Increasing obesity rates and growing levels of awareness among calorie-conscious consumers in North America have opened up new avenues for the weight management industry. The North American weight loss/obesity management market was estimated to be worth $104 billion in 2012. The quick results of weight loss surgeries and insurance coverage have made bariatric surgeries popular among clinically obese people. However, the considerable side-effects of these weight loss surgeries have made people opt for non-invasive and non-medical methods of weight loss. As per the American Society for Metabolic & Bariatric Surgery, the total number of weight loss surgeries performed in the U.S. was 220,000 in 2012, likely to increase in the coming years due to the rising obesity rate. In Canadian hospitals, a total of 2,385 bariatric procedures were carried out in 2008-2009; a 92% increase from 2004-2005. This research report categorizes the North America weight loss/obesity management market into weight loss diets, fitness and surgical equipment, and services. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the market is comprehensively analyzed at a granular level by geography (U.S. and Canada) to provide in-depth information on the North American scenario. Companies Mentioned: - Ajinomoto Co, Inc - Allergan, Inc - Amer Sports Corporation - Brunswick Corporation - Cynosure, Inc - EdietsCom - Equinox - Fitness First Group, Ltd - Gold's Gym International, Inc - Herbalife, Ltd - Icon Health & Fitness, Inc - Johnson Health Tech Co, Ltd - Life Time Fitness, Inc - Lifecore Fitness - Nestle Sa - Nutrisystem, Inc - Olympus Corporation - Pepsico, Inc - The Coca-Cola Co - Weight Watchers International, Inc For more information visit http://www.researchandmarkets.com/research/wj...th_america About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
DexCom Beats, Sees Narrower Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:40AM CST
Owing to narrower reported loss or adjusted earnings in the 2013-fourth quarter, shares of Dexcom rose 3.5% since the announcement of earnings results
Why Cynosure (CYNO) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:54AM CST
Cynosure has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy
25.8% Return Seen to Date on SmarTrend Cynosure Call (CYNO)
Comtex SmarTrend(R) - Thu Feb 20, 9:43AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on November 7th, 2013 at $23.71. In approximately 4 months, Cynosure has returned 25.80% as of today's recent price of $29.82.
Why Cynosure (CYNO) Could Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 7:57AM CST
Cynosure, a medical instruments manufacturer, could be a great candidate for another earnings beat
Masimo Q4 Earnings Meet Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 2:43PM CST
For full year 2013, adjusted earnings per share rose 11.5% to $1.16, in line with the Zacks Consensus Estimate.
Cynosure, Inc. (CYNO) Looks Good: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 7:44AM CST
Cynosure, Inc. was a big mover last session, as the company saw its shares rise nearly 6% on the day.
17.6% Return Seen to Date on SmarTrend Cynosure Call (CYNO)
Comtex SmarTrend(R) - Thu Feb 13, 9:26AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on November 7th, 2013 at $23.71. In approximately 3 months, Cynosure has returned 17.61% as of today's recent price of $27.88.
Cynosure Reports Record Fourth Quarter Revenue of $74.5 million, up 75% Year-over-Year
PR Newswire - Wed Feb 12, 7:00AM CST
Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced financial results for the three and 12 months ended December 31, 2013. Revenues for the fourth quarter increased 75% to $74.5 million from $42.7 million for the same period of 2012, while revenues for the full year of 2013 were up 47% to $226.0 million from $153.5 million for 2012. The increase partly reflects the acquisition of Palomar Medical Technologies in June 2013.
